Summary
ProMIS Neurosciences Inc (ProMIS) is a clinical-stage biotechnology company that focuses on the discovery and development of therapeutic antibodies. The company specializes in medical conditions like multiple system atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease that are marked by abnormal, misfolded proteins. Its PMN310, a monoclonal antibody (mAb), designated as its first lead product for development in Alzheimer's disease (AD). The company utilizes its patented technology platform to generate therapeutic antibody candidates that selectively target toxic forms of proteins without interfering with the functions of the healthy proteins. ProMIS is headquartered in Toronto, Ontario, Canada.This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company ProMIS Neurosciences Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- ProMIS Neurosciences Inc Company Overview
- ProMIS Neurosciences Inc Company Snapshot
- ProMIS Neurosciences Inc Pipeline Products and Ongoing Clinical Trials Overview
- ProMIS Neurosciences Inc - Pipeline Analysis Overview
- Business Description
- ProMIS Neurosciences Inc - Key Facts
- ProMIS Neurosciences Inc - Major Products and Services
- ProMIS Neurosciences Inc Pipeline Products by Development Stage
- ProMIS Neurosciences Inc Pipeline Products Overview
- Antibody Test - COVID-19
- Antibody Test - COVID-19 Product Overview
- Companion Diagnostic Test - ALS
- Companion Diagnostic Test - ALS Product Overview
- Companion Diagnostic Test - Alzheimer's Disease
- Companion Diagnostic Test - Alzheimer's Disease Product Overview
- EP-vCJD Assay
- EP-vCJD Assay Product Overview
- NfL Test - Alzheimer's Disease
- NfL Test - Alzheimer's Disease Product Overview
- P-tau181 Test - Alzheimer's Disease
- P-tau181 Test - Alzheimer's Disease Product Overview
- ProMIS - Cancer
- ProMIS - Cancer Product Overview
- Screening Test - Liver Cancer
- Screening Test - Liver Cancer Product Overview
- Serology Test - Immunity Assessment
- Serology Test - Immunity Assessment Product Overview
- ProMIS Neurosciences Inc - Key Competitors
- ProMIS Neurosciences Inc - Key Employees
- ProMIS Neurosciences Inc - Key Employee Biographies
- ProMIS Neurosciences Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- ProMIS Neurosciences Inc, Recent Developments
- Aug 06, 2024: ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
- Jun 30, 2023: ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
- Jun 29, 2023: ProMIS Annual Meeting of Shareholders on June 29, 2023
- Dec 16, 2021: ProMIS Neurosciences Issues Chairman’s Memorandum
- Oct 07, 2021: ProMIS Neurosciences Announces Special Shareholder Meeting
- May 25, 2021: ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
- Feb 02, 2021: ProMIS Neurosciences offers perspectives on recent progress in the Alzheimer’s/amyloid field
- Jan 12, 2021: ProMIS Neurosciences announces strategic priorities for 2021
- Jun 17, 2020: ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19
- May 19, 2020: ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- ProMIS Neurosciences Inc Pipeline Products and Ongoing Clinical Trials Overview
- ProMIS Neurosciences Inc Pipeline Products by Equipment Type
- ProMIS Neurosciences Inc Pipeline Products by Indication
- ProMIS Neurosciences Inc, Key Facts
- ProMIS Neurosciences Inc, Major Products and Services
- ProMIS Neurosciences Inc Number of Pipeline Products by Development Stage
- ProMIS Neurosciences Inc Pipeline Products Summary by Development Stage
- Antibody Test - COVID-19 - Product Status
- Antibody Test - COVID-19 - Product Description
- Companion Diagnostic Test - ALS - Product Status
- Companion Diagnostic Test - ALS - Product Description
- Companion Diagnostic Test - Alzheimer's Disease - Product Status
- Companion Diagnostic Test - Alzheimer's Disease - Product Description
- EP-vCJD Assay - Product Status
- EP-vCJD Assay - Product Description
- NfL Test - Alzheimer's Disease - Product Status
- NfL Test - Alzheimer's Disease - Product Description
- P-tau181 Test - Alzheimer's Disease - Product Status
- P-tau181 Test - Alzheimer's Disease - Product Description
- ProMIS - Cancer - Product Status
- ProMIS - Cancer - Product Description
- Screening Test - Liver Cancer - Product Status
- Screening Test - Liver Cancer - Product Description
- Serology Test - Immunity Assessment - Product Status
- Serology Test - Immunity Assessment - Product Description
- ProMIS Neurosciences Inc, Key Employees
- ProMIS Neurosciences Inc, Key Employee Biographies
- ProMIS Neurosciences Inc, Other Locations
- ProMIS Neurosciences Inc, Subsidiaries
- Glossary
- ProMIS Neurosciences Inc Pipeline Products by Equipment Type
- ProMIS Neurosciences Inc Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- WaveBreak Therapeutics Ltd
- Takeda Pharmaceutical Co Ltd
- Neurimmune Holding AG
- Inova Diagnostics Inc
- Idexx Laboratories Inc
- Diagnostica Stago Inc
- Chugai Pharmaceutical Co Ltd
- Grifols SA
- Acumen Pharmaceuticals Inc
- Novartis AG
- Eli Lilly and Co
- DiaSorin SpA
- Biogen Inc
- Anavex Life Sciences Corp
- Alzheon Inc
- Alector Inc
- Prothena Biosciences Inc
- Kalgene Pharmaceuticals Inc
- Eisai Co Ltd
- AbbVie Inc
- Cognition Therapeutics Inc
- Alzinova AB
- AC Immune SA
